Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability.
about
A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonismStructural and functional interactions between six-transmembrane μ-opioid receptors and β2-adrenoreceptors modulate opioid signalingOxytrex: an oxycodone and ultra-low-dose naltrexone formulationTolerance and withdrawal from prolonged opioid use in critically ill children.High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence.Expansion of the human mu-opioid receptor gene architecture: novel functional variantsOxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.Chronic pain: 2. The case for opioids.Advances in opioid antagonist treatment for opioid addiction.Prevalence of narcotic bowel syndrome in opioid abusers in iran.Opioids in cancer and chronic non-cancer pain therapy-indications and controversies.Pilot study of continuous co-infusion of morphine and naloxone in children with sickle cell pain crisisIn my opinion... opioid tolerance.Retrospective analysis of high-dose intrathecal morphine for analgesia after pelvic surgery.Can intellectualism stifle scientific discovery?Influence of clonidine and ketamine on m-RNA expression in a model of opioid-induced hyperalgesia in miceExploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity.Pain Management for Children during Bone Marrow and Stem Cell Transplantation.Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer.The optimal dose of prophylactic intravenous naloxone in ameliorating opioid-induced side effects in children receiving intravenous patient-controlled analgesia morphine for moderate to severe pain: a dose finding study.Differential Regulation of 6- and 7-Transmembrane Helix Variants of μ-Opioid Receptor in Response to Morphine StimulationEffects of combined opioids on pain and mood in mammals.Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.The narcotic bowel syndrome: clinical features, pathophysiology, and managementOpioids and the gastrointestinal tract - a case of narcotic bowel syndrome and literature review.Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study.Patient considerations in the use of tapentadol for moderate to severe pain.Mu opioids and their receptors: evolution of a concept.Molecular assays for characterization of alternatively spliced isoforms of the u opioid receptor (MOR).Tolerance and addiction; the patient, the parent or the clinician?Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature.Evidence from basic research for opioid combinations.Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.Diagnosis and treatment of narcotic bowel syndrome.The narcotic bowel syndrome: a recent update.μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.Naloxone prolongs cutaneous nociceptive block by lidocaine in rats.Low-Dose Naloxone for Prophylaxis of Postoperative Nausea and Vomiting: A Systematic Review and Meta-analysis.
P2860
Q24317131-B60FAA8F-1338-423A-B10D-9394C8FA72E4Q27303730-3F5CFAA8-6D69-4A7C-8112-8B6A64989AE2Q28239922-602E29FA-94AB-4CAC-9B9A-23A2E002ACCDQ30428413-243DD2D8-6A5E-49E2-8373-D64747C0BFF3Q33318465-91EDF458-F750-421B-9B86-61EBF66B2EACQ33395205-B61B9E7A-FE14-4C16-85DF-8B0783A97F17Q33793250-4AFB5619-0593-4CD2-9A05-0B216F09DA58Q33884718-0E687B99-468D-4B7B-8F6B-B5F5BA3D2CC6Q34044735-22B88C9B-16D3-48B1-B8ED-D406EC98DEDAQ34262649-8EA6FE7D-91C0-47B9-A932-59EB352A9674Q34401446-0A63FD22-17CE-40BE-84A9-37E3C5E8599CQ34421403-C9783CA6-DF1D-4CA1-8F4C-57B12035A376Q34582590-5AEB8162-1CFC-4EF8-96BB-CBC71681E133Q34618594-51BC9E45-F4B5-4B86-BD13-C2587A96F8BDQ34640904-E47A54D2-A669-46E4-BE4F-4FAA1A23ACEEQ34932240-9796C5E6-DC6F-4E24-807C-CB57737DB840Q35041398-AA4F7F2A-DA32-4134-A12D-660432ED77CFQ35122783-9321F8DA-17CE-4DE8-8611-F6B9B117389EQ35164063-212C61B7-47BE-4049-9E07-E8D7C3D8816DQ35220429-92861C32-EB06-448E-BF6B-AE23C1F85348Q35551918-7B4D1481-9055-4616-805D-17F245BC9B92Q35702950-2401E85C-F452-4AEE-AB48-760932E47033Q35837099-BA5B3D94-A678-4F8E-96EC-2E1002794470Q35884913-C3DA26BE-86D4-4951-BE41-3B81A994BAABQ36053125-AEF0D470-4839-43A3-B414-03C7DD4E69A5Q36136622-5A7EA26F-6135-48EE-B084-F0DDD56F64FFQ36542707-9A88B5A3-54BA-4A85-81BF-00FFB85A19EDQ36973386-5C3DE5E1-963D-4E70-BA0A-126A17550608Q36991981-1FAF28B9-B1FD-4AA0-AFCA-70B929E11470Q37236111-1B33421D-662C-4B11-B8FF-9D7DC40D51EEQ37718662-14489E14-2CB8-41F5-9175-B84B78C4E81CQ37825586-3D087644-2384-40C2-BE2B-8FB958D4E174Q37907386-ECCC13D9-4C8D-46C9-AEAA-A6F95B80234DQ37999097-54B11170-5CE1-476E-989B-42C7DE0FFC2DQ38097075-CAFD1ED2-56CF-4485-9C58-036A5BF05C07Q38206072-F7106E88-94ED-4F75-AEDC-58813A78BD6AQ38248064-30507B52-82F7-4E07-8ACF-A0248F0A0853Q38285112-6C22FBAD-E4B6-4855-B3CC-D170DCA7A7D3Q38693513-27C3CADB-67BA-446D-9652-A828255087B9Q38871780-7C21B11A-E68F-40B8-86AF-27C8DD8BA8F1
P2860
Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antagonists of excitatory opio ...... olerance/dependence liability.
@ast
Antagonists of excitatory opio ...... olerance/dependence liability.
@en
type
label
Antagonists of excitatory opio ...... olerance/dependence liability.
@ast
Antagonists of excitatory opio ...... olerance/dependence liability.
@en
prefLabel
Antagonists of excitatory opio ...... olerance/dependence liability.
@ast
Antagonists of excitatory opio ...... olerance/dependence liability.
@en
P1433
P1476
Antagonists of excitatory opio ...... olerance/dependence liability.
@en
P2093
P304
P356
10.1016/S0304-3959(99)00223-7
P407
P577
2000-02-01T00:00:00Z